Skip to main content

Table 6 Analysis of clinical, immunological characteristics and immunosuppressive therapy as predictors for AR in AR versus none AR cases

From: Multidrug resistant 1 (MDR1) C3435T and G2677T gene polymorphism: impact on the risk of acute rejection in pediatric kidney transplant recipients

Variables

AR group

N = 36

Non-AR

N = 47

OR

(95% CI)

P

Value

Age at transplant

Mean ± SD

9.4 (3.2%)

10 ± 2.8

0.953(0.819–1.109)

0.535

Sex

Male

N (%)

30 (83.3%)

35 (74.5%)

Reference

-

Female

N (%)

6 (16.7%)

12 (25.5%)

0.552(0.183–1.66)

0.290

Original kidney disease

NONE CAKUT

N (%)

17 (47.2%)

24 (51.1%)

Reference

-

CAKUT

N (%)

19 (52.8%)

23 (48.9%)

1.101 (0.640–1.893)

0.744

Dialysis before Tx

No

N (%)

2 (5.6%)

2 (4.3%)

Reference

-

Yes

N (%)

34 (94.4%)

45 (95.7%)

1.324(0.177–9.877)

0.785

Dialysis duration (months)

Median, IQR

12 (2–60)

12 (1–60)

0.979(0.936–1.025)

0.366

Donor/recipient HLA mismatch

4/6

N (%)

0

3 (6.4)

Reference

-

3/6

N (%)

22 (61.1)

28 (59.6)

-

0.1

2/6

N (%)

12 (33.3)

13 (27.7)

-

0.1

1/6

N (%)

2 (5.6)

1 (2.1)

-

0.1

0/6

N (%)

0

2 (4.3)

-

-

CMV risk stratification*

Low risk

N (%)

5 (13.9%)

3 (6.4%)

Reference

-

Intermediate

N (%)

30 (83.3%)

40 (85.1%)

0.607(0.239–1.543)

0.295

High risk

N (%)

1 (2.8%)

4 (8.5%)

0.313(0.068–1.452)

0.138

Antibody induction

Basiliximab

N (%)

15 (41.7%)

28 (59.6%)

Reference

-

ATG

N (%)

21 (58.3%)

19 (40.4%)

1.57(0.909–2.714)

0.106

Preemptive PEX

NO

N (%)

32 (88.9%)

36 (76.6%)

Reference

-

Yes

N (%)

4 (11.1%)

11 (23.4%)

0.577(0.275–1.215)

0.148

Maintenance IS other than TAC

MMF

N (%)

36 (100%)

46 (97.9%)

-

0.379

Azathioprine

N (%)

0 (0%)

1 (2.1%)

  
  1. AR; acute rejection, N; number, SD; standard deviation, IQR; interquartile range, CAKUT; congenital anomalies of kidney and urinary tract, CMV; cytomegalo virus, HLA; human leukocytic antigen, ATG: anti thymocyte globulin, PEX; plasma exchange, IS; immunosuppressive, TAC; tacrolimus, MMF; mycophenolic mofetil.* CMV IgG: Low risk (D -, R -), intermediate risk either (D+, R+) or (D-, R+), high risk (D+, R-), Logistic regression analysis test was used for statistical analysis